Consolidated Financial Results
for the Three Months Ended September 20, 2023
[Japanese GAAP]
October 30, 2023
Company name: Genky DrugStores Co., Ltd.
Stock exchange listing: Tokyo Stock Exchange
Code number: 9267
URL: http://www.genkydrugstores.co.jp
Representative: Kenichi Fujinaga, President
Contact: Takeshi Tsunemi, Executive Officer, Treasurer and General Manager, IR Division
Phone: +81-776-67-5240
Scheduled date of filing quarterly securities report: November 2, 2023
Scheduled date of commencing dividend payments: ―Availability of supplementary briefing material on quarterly financial results: Available
Schedule of quarterly financial results briefing session: Not Scheduled(Amounts of less than one million yen are rounded down.)
1. Consolidated Financial Results for the Three Months Ended September 20, 2023 (June 21, 2023 to September
20, 2023)(1) Consolidated Operating Results(% indicates changes from the previous corresponding period.)
Net income
Net sales
Operating income
Ordinary income
attributable to ownersof parent
Three months ended
Million yen%
Million yen%
Million yen%
Million yen%
September 20, 2023
46,871 10.0
2,015
27.2
2,089
23.7
1,444
31.1
September 20, 2022
42,6138.9
1,584(8.8)
1,688(8.8)
1,102 (10.6)(Note) Comprehensive income: Three months ended September 20, 2023: ¥1,442 million (30.9%)
Three months ended September 20, 2022: ¥1,102 million ((9.2)%)
Net income
per share
Three months ended
September 20, 2023
September 20, 2022

Diluted net
income per share
Yen

Yen

95.14
72.59

95.04
72.54

(2) Consolidated Financial Position
Total assets
Million yen

As of September 20,107,127
2023
As of June 20, 2023
105,912(Reference) Equity: As of September 20, 2023: ¥41,867 million
As of June 20, 2023: ¥40,607 million

Net assets

Equity ratio

Million yen%

41,95339.1

40,68138.3

2. Dividends
Annual dividends
1stquarter-end

2ndquarter-end
Yen

3rd
quarter-end
Yen

Year-end

Total

Yen

Yen

Yen

12.50
－－
Fiscal 2022－
Fiscal 2023
Fiscal 2023
12.50－(Forecast)(Note) Revision to the forecast for dividends announced most recently: No

12.50

25.00

12.50

25.00

3. Consolidated Financial Results Forecast for the Fiscal Year Ending June 20, 2024 (June 21, 2023 to June 20,2024)(% indicates changes from the previous corresponding period.)
Net income
Net income
Net sales
Operating income Ordinary income
attributable toper shareowners of parent
Million yen%

Million yen%

Million yen%

First half
89,500 6.7
3,450
2.5
3,600
1.1
Full year
180,000 6.5
7,000
4.3
7,250
2.4
(Note) Revision to the financial results forecast announced most recently: No

Million yen%

Yen

2,340
4,900

3.0
2.8

154.11322.71

Notes:(1) Changes in significant subsidiaries during the period under review (changes in specified subsidiaries resulting inchanges in scope of consolidation): No
Newly consolidated: None (Company Name); Removed from consolidation: None (Company Name)(2) Accounting policies adopted specially for the preparation of quarterly consolidated financial statements: No(3) Changes in accounting policies, changes in accounting estimates and retrospective restatement
1) Changes in accounting policies due to the revision of accounting standards: No
2) Changes in accounting policies other than 1) above: No
3) Changes in accounting estimates: No4) Retrospective restatement: No(4) Total number of issued shares (common stock)1) Total number of issued shares at the end of the period (including treasury stock):
As of September 20, 2023: 15,487,084 shares
As of June 20, 2023: 15,484,384 shares2) Total number of treasury stock at the end of the period:
As of September 20, 2023: 300,414 shares
As of June 20, 2023: 300,414 shares
3) Average number of shares during the period:
Three months ended September 20, 2023: 15,186,493 shares
Three months ended September 20, 2022: 15,182,504 shares* These quarterly financial results are outside the scope of quarterly reviews by a certified public accountant or anaudit corporation.
* Explanation of the proper use of financial results forecast and other notes
The earnings forecasts and other forward-looking statements herein are based on information that is available andcertain assumptions deemed reasonable as of the date of publication of this document. Actual results may differ
significantly from these forecasts due to a wide range of factors.